Pop­u­lar FDA com­mish Scott Got­tlieb has hand­ed in his res­ig­na­tion

In a stun­ning turn of events, FDA com­mis­sion­er Scott Got­tlieb is re­sign­ing from his post and leav­ing of­fice in a mat­ter of weeks.

The Wash­ing­ton Post re­port­ed that Got­tlieb, who’s been com­mut­ing from Con­necti­cut, told ad­min­is­tra­tion of­fi­cials that he wants to spend more time with his fam­i­ly.

Got­tlieb ar­rived at the FDA short­ly af­ter the Trump ad­min­is­tra­tion took of­fice, vow­ing to up­hold the gold stan­dard in drug de­vel­op­ment while do­ing every­thing pos­si­ble to fa­cil­i­tate drug mak­ers’ work — at least for the le­git­i­mate play­ers.

He has been enor­mous­ly pop­u­lar in his short stint, with the vast ma­jor­i­ty of bio­phar­ma ex­ecs ac­claim­ing his work at the agency. He’s al­so been pop­u­lar with Pres­i­dent Don­ald Trump, find­ing a se­cure spot for him­self in an ad­min­is­tra­tion not­ed for rapid turnover.

So what hap­pened here?

Just weeks ago Got­tlieb in­sist­ed on Twit­ter that ru­mors of his pend­ing de­par­ture from the agency were flat wrong. He tweet­ed:

We’ve got a lot im­por­tant pol­i­cy we’ll ad­vance this year. I look for­ward to shar­ing my 2019 strate­gic roadmap soon.

The big ques­tion now is who will re­place him. Trump freaked out many ex­ecs by en­ter­tain­ing Pe­ter Thiel’s push for a lib­er­tar­i­an ap­proach, which would have erased many of the bar­ri­ers to in­tro­duc­ing new drugs — along with the cred­i­bil­i­ty that goes with an FDA sanc­tion. Trump, though, has many open po­si­tions in his ad­min­is­tra­tion, in­clud­ing Cab­i­net-lev­el posts. Stephen Os­troff has tak­en the helm on a strict­ly in­ter­im ba­sis be­fore, but he re­tired last fall, re­placed by Wal­mart ex­ec­u­tive Frank Yian­nas.

Got­tlieb’s let­ter of res­ig­na­tion in­cludes his list of ac­com­plish­ments for the past 23 months, from a record num­ber of new drug ap­provals to their con­tin­ued work on mas­ter­ing new tech­nolo­gies and tak­ing on e-cig­a­rette use by mi­nors.

I’m con­fi­dent that the FDA will con­tin­ue to ad­vance all these ef­forts, and many oth­er goals.

In­dus­try lead­ers quick­ly not­ed the sig­nif­i­cance of the move to­day.

“We’re go­ing to miss him. He was a ter­rif­ic leader of the FDA,” Al­ny­lam CEO and BIO chair­man John Maraganore told me.

“It’s a damn shame,” Tweet­ed long­time se­r­i­al en­tre­pre­neur Mike Gilman, echo­ing the sharp lev­el of dis­ap­point­ment about the news.

 


Im­age: Scott Got­tlieb, com­mis­sion­er of the Food and Drug Ad­min­is­tra­tion (FDA), pos­es for por­trait pho­tographs in front of the old FDA sign at the FDA in White Oak, MD on No­vem­ber 5, 2018 The Wash­ing­ton Post

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

The race to de­vel­op Covid-19 drugs and vac­cines is on — here’s what’s hap­pen­ing in the UK

Weeks away from the results of ongoing US and China trials testing its experimental antiviral remdesivir, Gilead is going to trial the failed Ebola drug in a small group of coronavirus patients in England and Scotland. The United Kingdom is also home to a range of other therapeutic efforts, as the pandemic rages on across the globe.

On Tuesday, Southampton, UK-based startup Synairgen kicked off a mid-stage placebo-controlled study testing its experimental drug, SNG001 — an inhaled formulation of interferon-beta-1a — that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

‘There was a grow­ing weari­ness’: Rush­ing against a pan­dem­ic clock, As­pen Neu­ro­sciences se­cures $70M Se­ries A

Just before Christmastime, Howard Federoff got a tip from Washington: There was a new virus in China. And this one could be bad.

News report of the virus had not yet appeared. Federoff, a neuroscientist, was briefed because years before, he was vetted as part of a group — he didn’t give a name for the group — to consult for the US government on emerging scientific issues. His day job, though, was CEO of Aspen Neurosciences, a Parkinson’s cell therapy startup that days before had come out of stealth mode and gave word to investors they were hoping to raise $70 million. That, Federoff realized, would be difficult if a pandemic shut down the global economy.

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

Despite worries about regulatory delays due to new work arrangements under Covid-19, the FDA appears intent to go full speed ahead with its everyday work, not only granting priority review to a stem cell therapy for acute graft versus host disease but also plotting an advisory committee meeting for it.

With a PDUFA date of September 30, the journey of the drug — remestemcel-L, or Ryoncil — could shed light on the agency’s capacity to facilitate drug development unrelated to Covid-19.

Covid-19 roundup: Trump push­es his new fa­vorite, untest­ed drug; CRISPR out­lines crip­pling im­pact of Covid-19

President Trump has a new favorite Covid-19 drug.

After a conversation with Japanese Prime Minister Shinzo Abe, Politico reports, the president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally Rudy Giuliani has been talking up unproven cell therapy efforts on Twitter.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.